IP Library Granted Patent US 7,507,749
Granted Patent B2
US 7,507,749 · App. 11/753,197 · Granted Mar 24, 2009

Antitumor agents

Assignee: Wayne State University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,507,749
App. No.
11/753,197
Granted
Mar 24, 2009
Kind
B2
Abstract

The invention provides compounds of formula I: wherein Y is F, Cl, Br, methyl or methoxy; and pharmaceutically acceptable salts thereof. The compounds are effective antitumor agent. The invention also provides pharmaceutical compositions comprising a compound of formula I or a salt thereof, intermediates useful for preparing a compound of formula I, and therapeutic methods comprising administering a compound of formula I or a salt thereof to a mammal in need thereof.

Claims (29)

1. A therapeutic method to inhibit tumor cell growth in a mammal, comprising administering to a mammal in need of such therapy an effective amount of a composition comprising a compound of formula I:

wherein

Y is F, Cl, Br, methyl or methoxy; and

Z is an alkali metal cation or alkaline earth metal cation;

and a pharmaceutically acceptable diluent or carrier.

2. The method of claim 1 wherein the composition is formulated for oral, parenteral, intravenous, intramuscular, subcutaneous, or topical administration.

3. The method of claim 2 wherein Y is Cl or Br.

4. The method of claim 3 wherein Z of formula I is a Li cation, Na cation, K cation, Rb cation, Cs cation, Ca cation, Mg cation, or Ba cation.

5. The method of claim 4 wherein the composition is formulated for oral administration and is in the form of a tablet, buccal tablet, troche, capsule, elixir, suspension, syrup, or wafer.

6. The method of claim 5 wherein the composition comprises at least 0.1 weight % of the compound of formula I.

7. The method of claim 6 wherein the composition comprises between about 2 weight % to about 60 weight % of the compound of formula I.

8. The method of claim 2 wherein the composition is formulated for administration by infusion or injection, and the pharmaceutically acceptable diluent or carrier comprises water.

9. The method of claim 8 wherein the composition comprises at least 0.1 weight % of the compound of formula I.

10. The method of claim 9 wherein the composition comprises between about 2 weight % to about 60 weight % of the compound of formula I.

11. The method of claim 8 wherein the compound of formula I is encapsulated in a liposome.

12. The method of claim 2 wherein the configuration of the carbon indicated by the asterisk in formula I is the (R) configuration.

13. The method of claim 12 wherein the cancer is colon cancer, breast cancer, melanoma, pancreatic cancer, or leukemia.

14. The method of claim 13 wherein the cancer is pancreatic ductal adenocarcinoma, mammary adenocarcinoma, or colon carcinoma.

15. The method of claim 12 wherein the compound of formula I is (R) 2[4-(7-chloroquinolin-2-yloxy)phenoxy]propionic acid sodium salt or (R) 2[4-(7-bromoquinolin-2-yloxy)phenoxy]propionic acid sodium salt.

16. A therapeutic method to inhibit tumor cell growth in a mammal, comprising administering to a mammal in need of such therapy an effective amount of a composition comprising a compound of formula I:

wherein

Y is F, Cl, Br, methyl or methoxy;

Z is an alkali metal cation or alkaline earth metal cation; and

the configuration of the carbon indicated by the asterisk in formula I is the (R) configuration; and

a pharmaceutically acceptable diluent or carrier comprising water.

17. The method of claim 16 wherein the compound of formula I is (R) 2[4-(7-chloroquinolin-2-yloxy)phenoxy]propionic acid sodium salt or (R) 2[4-(7-bromoquinolin-2-yloxy)phenoxy]propionic acid sodium salt.

18. The method of claim 17 wherein the composition is formulated for oral, parenteral, intravenous, intramuscular, subcutaneous, or topical administration.

19. The method of claim 18 wherein the cancer is colon cancer, breast cancer, melanoma, pancreatic cancer, or leukemia.

20. The method of claim 19 wherein the cancer is pancreatic ductal adenocarcinoma, mammary adenocarcinoma, or colon carcinoma.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 26, 2012
From: WAYNE STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028643/0889 →
Continuity (4)
Continuation 1100945700 · Dec 10, 2004
Continuation 1021078100 · Jul 31, 2002
Provisional Application 6030914400 · Jul 31, 2001
Related Publication 20070232643A1 · Oct 4, 2007